Early research (Phase 1)Ended earlyNCT04800822What this trial is testingPF-07284892 in Participants With Advanced Solid TumorsWho this might be right forSolid Tumor Pfizer 53
Not applicableUnknownNCT06081270What this trial is testingProspective Study on Resistance-associated Mutations in Metastatic Lung CancerWho this might be right forLung Cancer University of Milano Bicocca 20
Testing effectiveness (Phase 2)UnknownNCT02968303What this trial is testingInduction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyWho this might be right forMelanoma, Malignant, of Soft Parts Radboud University Medical Center 200
Testing effectiveness (Phase 2)Ended earlyNCT04198818What this trial is testingEvaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced TumorsWho this might be right forAdvanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more Haihe Biopharma Co., Ltd. 37
Large-scale testing (Phase 3)Not Yet RecruitingNCT07440290What this trial is testingDETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.Who this might be right forHaematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+16 more Cancer Research UK 30
Testing effectiveness (Phase 2)Study completedNCT01116271What this trial is testingStudy of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With ColorecWho this might be right forColorectal Cancer AstraZeneca 32
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052What this trial is testingStudy of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid CancerWho this might be right forDifferentiated Thyroid Cancer (DTC) Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)Ended earlyNCT04985604What this trial is testingTovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsWho this might be right forMelanomaSolid TumorCRAF Gene Amplification+20 more Day One Biopharmaceuticals, Inc. 23
Testing effectiveness (Phase 2)Study completedNCT04620330What this trial is testingAvutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerWho this might be right forNon Small Cell Lung CancerKRAS Activating Mutation Verastem, Inc. 90
Early research (Phase 1)Study completedNCT01363232What this trial is testingSafety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor PatientsWho this might be right forAdvanced Solid TumorsSelected Solid Tumors Array Biopharma, now a wholly owned subsidiary of Pfizer 89
Testing effectiveness (Phase 2)Study completedNCT05068752What this trial is testingPhase II Trial of Vemurafenib and Sorafenib in Pancreatic CancerWho this might be right forPancreas Cancer HonorHealth Research Institute 10
Testing effectiveness (Phase 2)Looking for participantsNCT05786924What this trial is testingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesWho this might be right forNon-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Study completedNCT01086267What this trial is testingSafety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal CancerWho this might be right forColorectal Cancer Bristol-Myers Squibb 17
Early research (Phase 1)Ended earlyNCT07121829What this trial is testingTovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsWho this might be right forMelanomaSolid TumorPilocytic Astrocytoma+7 more Day One Biopharmaceuticals, Inc. 44
Early research (Phase 1)Study completedNCT01155453What this trial is testingInvestigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor PatientsWho this might be right forAdvanced and Selected Solid Tumors Novartis Pharmaceuticals 113
Testing effectiveness (Phase 2)Study completedNCT01781026What this trial is testingPhase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain MetastasesWho this might be right forMelanoma Yale University 2
Early research (Phase 1)Ended earlyNCT04249843What this trial is testingStudy of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory TumorsWho this might be right forSolid TumorB-Raf Mutation-Related Tumors MapKure, LLC 109
Not applicableStudy completedNCT01720758What this trial is testingAssessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative DiseaseWho this might be right forHairy Cell LeukemiaSplenic Marginal Zone Lymphoma HaEmek Medical Center, Israel 20
Early research (Phase 1)Active Not RecruitingNCT04913285What this trial is testingEvaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsWho this might be right forSolid Tumor, AdultNon-small Cell Lung CancerMelanoma Pierre Fabre Medicament 400
Early research (Phase 1)Ended earlyNCT06270082What this trial is testingStudy of IK-595 in RAS- or RAF-altered Advanced TumorsWho this might be right forSolid Tumor, AdultColorectal CancerPancreatic Cancer+7 more Ikena Oncology 75